e6vk
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of April 2008
Commission File Number 000-31062
Oncolytics Biotech Inc.
(Translation of registrant’s name into
English)
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): o
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a
Form 6-K if submitted solely to provide an attached annual report to security
holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): o
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a
Form 6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant’s “home country”), or under the rules of the home
country exchange on which the registrant’s securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrant’s security holders, and, if
discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
| |
|
|
|
|
| |
|
Oncolytics
Biotech Inc.
(Registrant) |
| |
| |
|
|
|
|
| |
| Date: April 9, 2008 |
|
By: |
|
/s/ Doug Ball
Doug Ball
Chief Financial Officer |
| |
|
|
|
|
210, 1167 Kensington Cr. N.W.
Calgary, Alberta
Canada T2N 1X7 |
| |
|
|
|
FOR IMMEDIATE RELEASE
Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination
REOLYSIN® and Carboplatin/Paclitaxel Trial
CALGARY, AB, — April 9, 2008 — Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY)
today announced positive interim results from its U.K. combination REOLYSIN® and
carboplatin/paclitaxel trial. Dr. Kevin Harrington of The Institute of Cancer Research, London,
and the principal investigator for the trial, presented the results today at The 5th
Annual Conference of the British Society for Gene Therapy (BSGT) in Edinburgh, Scotland.
Four of the first eight patients treated in the study to date have a diagnosis of carcinoma of the
head and neck. All three head and neck patients evaluated to date have had excellent clinical and
radiological responses without appreciable toxicity. Preliminary assessment after recruitment of
the first two cohorts has suggested that patients with head and neck carcinomas may represent a
group of patients in whom the combination of carboplatin/paclitaxel and REOLYSIN® is
active.
“These early results in head and neck patients are remarkable, considering the prognosis for
refractory patients is generally poor,” said Dr. Karl Mettinger, Chief Medical Officer for
Oncolytics.
In the first cohort, the patient with head and neck cancer received 8 cycles of treatment (the
maximum allowed) and achieved a clinical complete response. In the second cohort, the two patients
with head and neck cancers with widespread disseminated disease have each received six cycles of
treatment to date and both have achieved significant partial responses. Two of the three
patients, including the patient with the clinical complete response, had previously received
cisplatin/5-FU treatment and all three had previously received radiotherapy.
More information about this clinical trial, including CT scans from selected patients enrolled on
the trial, can be found on the Oncolytics website at www.oncolyticsbiotech.com.
The primary objective of the trial is to determine the Maximum Tolerated Dose (MTD), Dose-Limiting
Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN®
when administered in combination with paclitaxel and carboplatin. Secondary objectives include the
evaluation of immune response to the drug combination, the body’s response to the drug combination
compared to chemotherapy alone and any evidence of anti-tumour activity.
The principal investigators are Dr. Kevin Harrington of The Institute of Cancer Research and The
Royal Marsden NHS Foundation Trust, and Dr. Geoff Hall of St. James’s Hospital in Leeds, U.K.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics’ clinical program includes a variety of Phase I/II
and Phase II human trials using REOLYSIN®, its proprietary formulation of the human
reovirus, alone and in combination with radiation or chemotherapy. For further information about
Oncolytics, please visit www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company’s
expectations related to the U.K. combination REOLYSIN® and carboplatin/paclitaxel
clinical trial, and the Company’s belief as to the potential of REOLYSIN® as a cancer
therapeutic, involve known and unknown risks and uncertainties, which could cause the Company’s
actual results to differ materially from those in the forward-looking statements. Such risks and
uncertainties include, among others, the availability of funds and resources to pursue research and
development projects, the efficacy of REOLYSIN® as a cancer treatment, the success and
timely completion of clinical studies and trials, the Company’s ability to successfully
commercialize REOLYSIN®, uncertainties related to the research and development of
pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the
Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for
additional information on risks and uncertainties relating to the forward-looking statements.
Investors are cautioned against placing undue reliance on forward-looking statements. The Company
does not undertake to update these forward-looking statements.
FOR FURTHER INFORMATION PLEASE CONTACT:
| |
|
|
|
|
Oncolytics Biotech Inc.
Cathy Ward
210, 1167 Kensington Cr NW
Calgary, Alberta T2N 1X7
Tel: 403.670.7377
Fax: 403.283.0858
cathy.ward@oncolytics.ca
|
|
The Equicom Group
Nick Hurst
325, 300 5th Ave. SW
Calgary, Alberta T2P 3C4
Tel: 403.538.4845
Fax: 403.237.6916
nhurst@equicomgroup.com
|
|
The Investor Relations Group
Erika Moran
11 Stone St, 3rd Floor
New York, NY 10004
Tel: 212.825.3210
Fax: 212.825.3229
emoran@investorrelationsgroup.com |
